Na Li
- Oncology top 1%
- Molecular Biology top 5%
- Immunology top 2%
- Biomedical Engineering top 5%
- Genetics top 5%
- Co-authors
- Darrell J. IrvineHaoyi WangXingying ZhangXiaofei WeiWei MuWeidong HanXianquan ZhanMariane B. Melo
- Topics
- RNA modifications and cancer (32 papers)Ferroptosis and cancer prognosis (21 papers)Cancer-related molecular mechanisms research (21 papers)
- Cited by
- OncologyImmunologyCancer Research
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Na Li
103 papers receiving 3.4k citations
Hit Papers
Peers
Comparison fields: 5 of 118
- Oncology 1.9k
- Molecular Biology 1.6k
- Immunology 1.0k
- Biomedical Engineering 890
- Genetics 510
Countries citing papers authored by Na Li
This map shows the geographic impact of Na Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Na Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Na Li more than expected).
Fields of papers citing papers by Na Li
This network shows the impact of papers produced by Na Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Na Li. The network helps show where Na Li may publish in the future.
Co-authorship network of co-authors of Na Li
This figure shows the co-authorship network connecting the top 25 collaborators of Na Li. A scholar is included among the top collaborators of Na Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Na Li. Na Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 0 | |
| 3 | 3 | |
| 4 | 2 | |
| 5 | 3 | |
| 6 | 1 | |
| 7 | 4 | |
| 8 | 4 | |
| 9 | 14 | |
| 10 | 10 | |
| 11 | 1 | |
| 12 | 9 | |
| 13 | 9 | |
| 14 | 29 | |
| 15 | 27 | |
| 16 | TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumorsbreakdown → | 293 |
| 17 | Enhanced CAR–T cell activity against solid tumors by vaccine boosting through the chimeric receptorbreakdown → | 319 |
| 18 | 1 | |
| 19 | 61 | |
| 20 | Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug deliverybreakdown → | 542 |
About Na Li
Na Li is a scholar working on Cancer Research, Infectious Diseases and Oncology, having authored 112 papers that have together received 3.4k indexed citations. Recurring topics across this work include RNA modifications and cancer (32 papers), Ferroptosis and cancer prognosis (21 papers) and Cancer-related molecular mechanisms research (21 papers). The work is most often cited by research in Oncology (1.9k citations), Immunology (1.0k citations) and Cancer Research (465 citations). Na Li has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Darrell J. Irvine, Haoyi Wang, Xingying Zhang, Xiaofei Wei, Wei Mu, Weidong Han, Xianquan Zhan, Mariane B. Melo, Li Tang and Yiran Zheng. Their work appears in journals such as Science, Cell and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.